IASOCHOLINE (fluorocholine (18F) chloride), radiopharmaceutical for diagnostic use

• IASOCHOLINE has Marketing Authorisation:

- In the detection and localisation of bone metastases in prostate cancer.
- In the localisation of known lesions of well-differentiated hepatocellular carcinoma and the characterisation of liver nodules and/or staging of known or very likely lesions of hepatocellular carcinoma.

• This is an ¹⁸F-labelled radiopharmaceutical product for imaging with positron emission tomography (PET) which only has clinical added value in the detection of bone metastases in prostate cancer but has not shown any diagnostic benefit in the localisation of lesions of hepatocellular carcinoma.